Despite promising clinical evidence, copyright's Vyndamax, a treatment for hereditary transthyretin-mediated amyloidosis (hATTR), is encountering substantial resistance from pharmacy benefit managers. These companies are often building limitations to coverage, such as high cost restrictions and PA that hinder user availability. Analysts suggest tha